NeuroOne Announces Fiscal Third Quarter 2026 Financial Results Conference Call

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, will release its financial results for the fiscal third quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The announcement, made via NewMediaWire on August 3, 2026, underscores the company's ongoing commitment to transparency and investor communication as it advances its innovative electrode technology platform.

The upcoming earnings release is a key event for investors and healthcare professionals monitoring the company's performance. NeuroOne has established itself as a player in the neurological device space with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products are designed to offer minimally invasive, high-definition diagnostic and therapeutic solutions, potentially reducing hospitalizations, surgical procedures, and overall healthcare costs while improving patient outcomes.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day to discuss the financial results, provide a corporate update, and answer questions from telephone participants. The call details include U.S. toll-free dial-in at 888-506-0062 and international dial-in at 973-528-0011, with participant access code 549778. A live webcast will be accessible via the provided link, and participants are encouraged to join at least five minutes early to ensure timely participation.

The company's strategic focus extends beyond its current product lines, with research and development efforts underway in drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. These initiatives indicate a forward-looking approach to expanding its technology platform and addressing a broader range of neurological conditions. The financial results and corporate update on August 13 will likely provide insights into the progress of these R&D projects and overall business momentum.

For those unable to attend the live call, a playback will be available through Thursday, August 27, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) and using replay passcode 54304. Additionally, a webcast replay will be accessible on the same link until August 13, 2027, ensuring that stakeholders have ample opportunity to review the company's performance.

NeuroOne's commitment to innovation and its growing portfolio of FDA-cleared products position it as a notable entity in the medical technology sector. The upcoming financial results and conference call will be crucial for investors to assess the company's fiscal health and strategic direction. With a focus on improving surgical outcomes and reducing healthcare burdens, NeuroOne continues to make strides in the field of neurological care.